Similar articles

• The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.

  Lin TH, Huang CH, Voon WC, Yen HW, Lai HM, Liang HY, Lu YH, Lee KT, Lee CS, Lai WT, Sheu SH. Lin TH, et al. Kaohsiung J Med Sci. 2000 Dec;16(12):600-6. Kaohsiung J Med Sci. 2000. PMID: 11392099
• Short-term effects of fluvastatin, a hydroxylmethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia.

  Saito M, Asakura H, Morishita E, Yamazaki M, Matsuda T. Saito M, et al. Int J Hematol. 1999 Jun;69(4):274-6. Int J Hematol. 1999. PMID: 10407589 No abstract available.
• Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.

  Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G. Bevilacqua M, et al. Am J Cardiol. 1997 Jan 1;79(1):84-7. doi: 10.1016/s0002-9149(96)00684-4. Am J Cardiol. 1997. PMID: 9024745 Clinical Trial.
• [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].

  Carmena R. Carmena R. Rev Esp Cardiol. 1995 Jan;48(1):59-65. Rev Esp Cardiol. 1995. PMID: 7878284 Review. Spanish. No abstract available.
• Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.

  Hsu I, Spinler SA, Johnson NE. Hsu I, et al. Ann Pharmacother. 1995 Jul-Aug;29(7-8):743-59. doi: 10.1177/106002809502907-818. Ann Pharmacother. 1995. PMID: 8520093 Review.